



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918
FAX : 022-2493 0534 / 2493 9633
e-mail : info@jbcpl.com
Website : www.jbcpl.com
CIN : L24390MH1976PLC019380

StockExchange-NSE letters/MM:SA:616

May 20, 2016

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Outcome of the Meeting of the board of directors

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find:

1. Standalone audited financial results for the year ended on March 31, 2016 alongwith Auditor's Report and Form A (for audit report with unmodified opinion).
2. Consolidated audited financial results for the year ended on March 31, 2016 alongwith Auditor's Report and Form A (for audit report with unmodified opinion).

These financial results have been approved and taken on record by the board of directors at its meeting held today.

The meeting of the Board of Directors commenced at 11.45 a.m. and concluded at 3.00 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta
Company Secretary and Vice President - Compliance

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

'NEELAM CENTRE', 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380


STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2016

(Rs. In Lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2016	31-12-2015	31-03-2015	31-03-2016	31-03-2015	31-03-2016	31-03-2015
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Income from Operations							
	a. Net sales (Net of excise duty)	28,948.90	27,058.46	24,975.71	1,11,993.24	1,03,813.61	1,22,663.84	1,12,065.91
	b. Other Operating Income	933.51	776.95	533.52	2,823.53	2,328.51	2,850.55	2,355.57
	Total Income from Operations (Net) (a+b)	29,882.41	27,835.41	25,509.23	1,14,816.77	1,06,142.12	1,25,514.39	1,14,421.48
2	Expenses							
	a. Cost of materials consumed	8,967.58	9,497.53	8,705.22	37,307.84	34,158.73	37,307.84	34,158.73
	b. Purchases of stock-in-trade	2,821.41	1,073.13	1,906.91	8,207.33	9,009.66	14,532.13	12,399.29
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(651.13)	(395.41)	(277.20)	(636.50)	(68.24)	(2,479.30)	(1,608.93)
	d. Employees benefits expense	4,709.81	3,910.55	3,858.93	16,750.56	14,681.81	18,411.99	15,955.63
	e. Depreciation and amortization expense	1,037.00	1,022.56	757.99	4,040.56	3,759.99	4,123.62	3,864.12
	f. Exchange Fluctuation Transactional (Gain)/Loss	1,375.25	66.70	39.94	1,647.45	58.16	2,399.36	1,275.38
	g. Other Expenses	7,143.88	7,222.56	7,053.92	29,243.46	28,633.60	34,889.10	32,984.14
	Total Expenses	25,403.80	22,397.62	22,045.71	96,560.70	90,233.71	1,09,184.75	99,028.36
3	Profit from Operations before Other Income, Finance Cost (1-2)	4,478.61	5,437.79	3,463.52	18,256.07	15,908.41	16,329.64	15,393.12
4	Other Income	920.06	1,290.99	150.48	5,292.39	1,040.88	5,415.84	1,089.34
5	Profit before Finance Cost (3+4)	5,398.67	6,728.78	3,614.00	23,548.46	16,949.29	21,745.48	16,482.46
6	Finance Cost	183.00	259.83	22.33	922.27	665.01	957.38	682.42
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	5,215.67	6,468.95	3,591.67	22,626.19	16,284.28	20,788.10	15,800.04
8	Exchange Fluctuation Translation Gain / (Loss)	127.99	35.27	280.94	83.41	(373.86)	94.35	(1,245.23)
9	Profit before Tax (7+8)	5,343.66	6,504.22	3,872.61	22,709.60	15,910.42	20,882.45	14,554.81
10	Tax expenses	1,020.75	1,515.00	1,298.97	5,070.75	4,552.17	4,690.93	4,514.30
11	Net Profit/(Loss) after Tax (9-10)	4,322.91	4,989.22	2,573.64	17,638.85	11,358.25	16,191.52	10,040.51
12	Minority Interest	-	-	-	-	-	3.50	-
13	Net Profit/(Loss) after Tax and Minority Interest (11-12)	4,322.91	4,989.22	2,573.64	17,638.85	11,358.25	16,188.02	10,040.51
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.40	1,696.16	1,696.40	1,696.16	1,696.16	1,696.16
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	1,12,478.57	99,934.99	1,07,676.77	97,791.26
16	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)							
	(1) Basic	5.10	5.88	3.04	20.80	13.40	19.09	11.84
	(2) Diluted	5.10	5.88	3.03	20.80	13.39	19.09	11.84

NOTES

- The above audited financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on May 20 2016.
- The Board of Directors has recommended a final dividend of Re.0.50 per equity share of FV of Rs. 2. During the year, the Company has paid interim dividend of Rs. 4.50 (225%) per equity share of FV of Rs. 2. These dividends would result in total outgo of Rs. 5,104.38 lacs including dividend distribution tax.
- The other income for the quarter includes exchange gain of Rs. 12.11 crores and the other expenses include exchange loss of Rs. 0.72 crores arising on account of return of capital due to dissolution of a subsidiary company, both of which are non-recurring in nature. The other income for the financial year includes gain of Rs. 33.71 crores realised on redemption of mutual funds units.
- The consolidated profit before tax for the year is affected by Rs.18.27 crores primarily due to depreciation in value of Ruble against USD during the financial year.
- During Q3, the company's subsidiary Unique Pharmaceutical Laboratories FZE ("UPL FZE") acquired 21,94,030 ordinary shares in Biotech Laboratories (Pty.) Ltd. ("Biotech"). Consequent to restructuring of the existing shareholding in Biotech and issue of certain additional shares by Biotech after the aforesaid acquisition, UPL FZE now holds 95.24% voting capital of Biotech against 49% earlier held by the Company's subsidiary J.B. Healthcare Pvt. Ltd. The said subsidiary J.B. Healthcare Pvt. Ltd. has now been dissolved.
- The Central Government issued notifications on March 10, 2016, banning about 344 fixed dose combinations for sale in the domestic market. The Company's five formulations have been covered these notifications. The Company has challenged the notifications affecting the Company before Hon'ble Delhi High Court, which has presently stayed these notifications. However, the sales of these formulations are not material keeping in view the size of the Company's domestic business.
- The figures for the quarter ended on March 31, 2016 are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third quarter ended on December 31, 2015.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The previous quarter's/period's figures have been regrouped/re-stated, wherever necessary.



Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

10. The statement of assets and liabilities as on March 31, 2016 is as under:

	Particulars	Standalone		Consolidated	
		AS AT 31-03-2016	AS AT 31-03-2015	AS AT 31-03-2016	AS AT 31-03-2015
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	a. Share Capital	1,696.40	1,696.16	1,696.40	1,696.16
	b. Reserves and surplus	1,12,478.57	99,934.99	1,07,676.77	97,791.26
	Sub Total of Shareholders' funds	1,14,174.97	1,01,631.15	1,09,373.17	99,487.42
2	Minority Interest	0.00	0.00	159.60	0.00
3	Non-current liabilities				
	a. Long-term borrowings	0.00	40.00	0.00	40.00
	b. Deferred tax liabilities (Net)	2,282.97	2,162.22	1,582.40	2,019.76
	c. Long-term provisions	1,020.11	1,202.60	1,043.29	1,202.60
	Sub-Total - Non-current liabilities	3,303.08	3,404.82	2,625.69	3,262.36
3	Current liabilities				
	a. Short-term borrowings	17,440.19	10,472.97	19,302.37	12,687.95
	b. Trade payables	6,860.93	6,230.76	9,085.09	7,751.39
	c. Other current liabilities	11,899.93	8,259.92	13,482.57	10,373.85
	d. Short-term provisions	1,133.13	14,876.41	1,709.92	15,161.72
	Sub-Total - Current liabilities	37,334.18	39,840.06	43,579.95	45,974.91
	TOTAL-EQUITY AND LIABILITIES	1,54,812.23	1,44,876.03	1,55,738.41	1,48,724.69
B	ASSETS				
1	Non-current assets				
	a. Fixed assets	50040.35	35604.09	57126.94	38,373.42
	b. Non-current investments	31779.80	23071.57	18483.12	18,483.24
	c. Long-term loans and advances	2339.04	1761.91	2352.69	1,774.44
	Sub-Total - Non-current assets	84159.19	60437.57	77962.75	58,631.10
2	Current assets				
	a. Current investments	19524.97	36678.17	19524.97	36,678.17
	b. Inventories	13329.31	12847.40	18798.33	15,027.33
	c. Trade receivables	26802.32	24849.05	27518.79	26,234.82
	d. Cash and cash equivalents	1080.03	905.52	1495.67	2,518.76
	e. Short-term loans and advances	9916.41	9158.32	10437.90	9,634.51
	Sub-Total - Current assets	70653.04	84438.46	77775.66	90,093.59
	Total-Assets	154812.23	144876.03	155738.41	1,48,724.69

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai
Date : May 20, 2016


J.B. Mody
Chairman & Managing Director



**Auditors' Report on the Standalone Financial Results of J. B. Chemicals and Pharmaceuticals Limited
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,
The Board of Directors
J. B. Chemicals and Pharmaceuticals Limited
Mumbai, India.

We have audited the accompanying Statement of Standalone Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Company") for the year ended 31st March, 2016 ("the Statement"), being submitted by the company pursuant to the requirement of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, have been prepared on the basis of the related financial statements which are in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.


We have conducted our audit in accordance, with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform audit to obtain reasonable assurance about whether the Statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the Statement. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that the audit evidence, we have obtained is sufficient and appropriate to provides a basis for our audit opinion.

In our opinion and to the best of our information and according to the explanations given to us, the Statement;

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ; and
- ii. give a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial information of the Company for the year ended 31st March, 2016

The Statement includes the results for the Quarter ended 31st March, 2016 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to Limited Review by us.

For J K Shah & Co
Chartered Accountants
Firm's Registration No. : 109606W


J. K. Shah
Partner

Membership No. 3662
Place: Mumbai
Date: 20th May, 2016





J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI.
MUMBAI - 400 030.


PHONE : 022-2482 2222 / 2493 0918
FAX : 022-2493 0534 / 2493 9633
e-mail : info@jbcpl.com
Website : www.jbcpl.com
CIN : L24390MH1976PLC019380

May 20, 2016

FORM - A

1	Name of the company	J.B. Chemicals & Pharmaceuticals Limited
2	Annual Financial Statements for the year ended	31 st March, 2016 - Standalone
3	Type of Audit Observation	Un modified
4	Frequency of observation	Not Applicable

For J.B. Chemicals & Pharmaceuticals Ltd.


J.B. Mody


Chairman & Managing Director


J. K. Shah & Co.
Auditor of the company


Vijay D. Bhatt
Chief Financial Officer


Durga Dass Chopra
Audit Committee Chairman





J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918
FAX : 022-2493 0534 / 2493 9633
e-mail : info@jbcpl.com
Website : www.jbcpl.com
CIN : L24390MH1976PLC019380


STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2016

(Rs. in Lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2016	31-12-2015	31-03-2015	31-03-2016	31-03-2015	31-03-2016	31-03-2015
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Income from Operations							
	a. Net sales (Net of excise duty)	28,948.90	27,058.46	24,975.71	1,11,993.24	1,03,817.61	1,22,663.84	1,12,065.91
	b. Other Operating Income	933.51	776.95	533.52	2,823.53	2,328.51	2,850.55	2,355.57
	Total Income from Operations (Net) (a+b)	29,882.41	27,835.41	25,509.23	1,14,816.77	1,06,146.12	1,25,514.39	1,14,421.48
2	Expenses							
	a. Cost of materials consumed	8,967.58	9,497.53	8,705.22	37,307.84	34,158.73	37,307.84	34,158.73
	b. Purchases of stock-in-trade	2,821.41	1,073.13	1,906.91	8,207.33	9,009.66	14,532.13	12,399.29
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(651.13)	(395.41)	(277.20)	(636.50)	(68.24)	(2,479.30)	(1,608.93)
	d. Employees benefits expense	4,709.81	3,910.55	3,858.93	16,750.56	14,681.81	18,411.99	15,955.63
	e. Depreciation and amortization expense	1,037.00	1,022.56	757.99	4,040.56	3,759.99	4,123.62	3,864.12
	f. Exchange Fluctuation Transactional (Gain)/Loss	1,375.25	66.70	39.94	1,647.45	58.16	2,399.36	1,275.38
	g. Other Expenses	7,143.88	7,222.56	7,053.92	29,243.46	28,633.60	34,889.10	32,984.14
	Total Expenses	25,403.80	22,397.62	22,045.71	96,560.70	90,233.71	1,09,184.75	99,028.36
3	Profit from Operations before Other Income, Finance Cost (1-2)	4,478.61	5,437.79	3,463.52	18,256.07	15,908.41	16,329.64	15,393.12
4	Other Income	920.06	1,290.99	150.48	5,292.39	1,040.88	5,415.84	1,089.34
5	Profit before Finance Cost (3+4)	5,398.67	6,728.78	3,614.00	23,548.46	16,949.29	21,745.48	16,482.46
6	Finance Cost	183.00	259.83	22.33	922.27	665.01	957.38	682.42
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	5,215.67	6,468.95	3,591.67	22,626.19	16,284.28	20,788.10	15,800.04
8	Exchange Fluctuation Translation Gain / (Loss)	127.99	35.27	280.94	83.41	(373.86)	94.35	(1,245.23)
9	Profit before Tax (7+8)	5,343.66	6,504.22	3,872.61	22,709.60	15,910.42	20,882.45	14,554.81
10	Tax expenses	1,020.75	1,515.00	1,298.97	5,070.75	4,552.17	4,690.93	4,514.30
11	Net Profit/(Loss) after Tax (9-10)	4,322.91	4,989.22	2,573.64	17,638.85	11,358.25	16,191.52	10,040.51
12	Minority Interest	-	-	-	-	-	3.50	-
13	Net Profit/(Loss) after Tax and Minority Interest (11-12)	4,322.91	4,989.22	2,573.64	17,638.85	11,358.25	16,188.02	10,040.51
14	Paid Up Equity Share Capital (Face Value Rs. 2/-)	1,696.40	1,696.40	1,696.16	1,696.40	1,696.16	1,696.16	1,696.16
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	1,12,478.57	99,934.99	1,07,676.77	97,791.26
16	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)							
	(1) Basic	5.10	5.88	3.04	20.80	13.40	19.09	11.84
	(2) Diluted	5.10	5.88	3.03	20.80	13.39	19.09	11.84

NOTES

- The above audited financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on May 20 2016.
- The Board of Directors has recommended a final dividend of Re.0.50 per equity share of FV of Rs. 2. During the year, the Company has paid interim dividend of Rs. 4.50 (225%) per equity share of FV of Rs. 2. These dividends would result in total outgo of Rs. 5,104.38 lacs including dividend distribution tax.
- The other income for the quarter includes exchange gain of Rs. 12.11 crores and the other expenses include exchange loss of Rs. 0.72 crores arising on account of return of capital due to dissolution of a subsidiary company, both of which are non-recurring in nature. The other income for the financial year includes gain of Rs. 33.71 crores realised on redemption of mutual funds units.
- The consolidated profit before tax for the year is affected by Rs.18.27 crores primarily due to depreciation in value of Ruble against USD during the financial year.
- During Q3, the company's subsidiary Unique Pharmaceutical Laboratories FZE ("UPL FZE") acquired 21,94,030 ordinary shares in Biotech Laboratories (Pty.) Ltd. ("Biotech"). Consequent to restructuring of the existing shareholding in Biotech and issue of certain additional shares by Biotech after the aforesaid acquisition, UPL FZE now holds 95.24% voting capital of Biotech against 49% earlier held by the Company's subsidiary J.B. Healthcare Pvt. Ltd. The said subsidiary J.B. Healthcare Pvt. Ltd. has now been dissolved.
- The Central Government issued notifications on March 10, 2016, banning about 344 fixed dose combinations for sale in the domestic market. The Company's five formulations have been covered these notifications. The Company has challenged the notifications affecting the Company before Hon'ble Delhi High Court, which has presently stayed these notifications. However, the sales of these formulations are not material keeping in view the size of the Company's domestic business.
- The figures for the quarter ended on March 31, 2016 are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third quarter ended on December 31, 2015.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The previous quarter's/period's figures have been regrouped/re-stated, wherever necessary.





J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918
FAX : 022-2493 0534 / 2493 9633
e-mail : info@jbcpl.com
Website : www.jbcpl.com
CIN : L24390MH1976PLC019380

10. The statement of assets and liabilities as on March 31, 2016 is as under:

	Particulars	Standalone		Consolidated	
		AS AT 31-03-2016	AS AT 31-03-2015	AS AT 31-03-2016	AS AT 31-03-2015
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
a.	Share Capital	1,696.40	1,696.16	1,696.40	1,696.16
b.	Reserves and surplus	1,12,478.57	99,934.99	1,07,676.77	97,791.26
	Sub Total of Shareholders' funds	1,14,174.97	1,01,631.15	1,09,373.17	99,487.42
2	Minority Interest	0.00	0.00	159.60	0.00
3	Non-current liabilities				
a.	Long-term borrowings	0.00	40.00	0.00	40.00
b.	Deferred tax liabilities (Net)	2,282.97	2,162.22	1,582.40	2,019.76
c.	Long-term provisions	1,020.11	1,202.60	1,043.29	1,202.60
	Sub-Total - Non-current liabilities	3,303.08	3,404.82	2,625.69	3,262.36
3	Current liabilities				
a.	Short-term borrowings	17,440.19	10,472.97	19,302.37	12,687.95
b.	Trade payables	6,860.93	6,230.76	9,085.09	7,751.39
c.	Other current liabilities	11,899.93	8,259.92	13,482.57	10,373.85
d.	Short-term provisions	1,133.13	14,876.41	1,709.92	15,161.72
	Sub-Total - Current liabilities	37,334.18	39,840.06	43,579.95	45,974.91
	TOTAL-EQUITY AND LIABILITIES	1,54,812.23	1,44,876.03	1,55,738.41	1,48,724.69
B	ASSETS				
1	Non-current assets				
a.	Fixed assets	50040.35	35604.09	57126.94	38,373.42
b.	Non-current investments	31779.80	23071.57	18483.12	18,483.24
c.	Long-term loans and advances	2339.04	1761.91	2352.69	1,774.44
	Sub-Total - Non-current assets	84159.19	60437.57	77962.75	58,631.10
2	Current assets				
a.	Current Investments	19524.97	36678.17	19524.97	36,678.17
b.	Inventories	13329.31	12847.40	18798.33	15,027.33
c.	Trade receivables	26802.32	24849.05	27518.79	26,234.82
d.	Cash and cash equivalents	1080.03	905.52	1495.67	2,518.76
e.	Short-term loans and advances	9916.41	9158.32	10437.90	9,634.51
	Sub-Total - Current assets	70653.04	84438.46	77775.66	90,093.59
	Total-Assets	154812.23	144876.03	155738.41	1,48,724.69

For J.B. Chemicals & Pharmaceuticals Ltd.


J.B. Mody
Chairman & Managing Director

Place : Mumbai
Date : May 20, 2016



**Auditors' Report on the Consolidated Financial Results of J. B. Chemicals and Pharmaceuticals Limited
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,
The Board of Directors
J. B. Chemicals and Pharmaceuticals Limited
Mumbai, India

We have audited the accompanying Statement of Consolidated Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Holding Company") and its Subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its Joint Venture, for the year ended 31st March, 2016 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared on the basis of the related consolidated financial statements which are in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act 2013 as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.

We have conducted our audit in accordance, with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform audit to obtain reasonable assurance about whether the Statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the Statement. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that the audit evidence, we have obtained is sufficient and appropriate to provides a basis for our audit opinion.

We did not audit the financial statements / financial information of two subsidiaries included in the consolidated year to date results, whose financial statements reflect total assets of ₹ 18,305.29 Lacs at 31st March, 2016, as well as the total revenue of ₹ 12,677.50 Lacs for the year ended on that date. These financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the year to date financial results, to the extent they have been derived from such financial statements is based solely on the report of such other auditors.

We did not audit the financial statements/financial information of a joint venture and three subsidiaries whose financial statements/financial information reflect total assets of ₹ 8,444.31 Lacs as at 31st March, 2016 as well as the total revenues of ₹ 10,366.12 Lacs for the year ended on that date. These financial statements/ financial information are unaudited and have been furnished to us by the Management and our opinion on the year to date financial results, in so far as it relates to the aforesaid joint venture and subsidiaries is based solely on such unaudited financial statements / financial information.



J.K. SHAH & CO.
CHARTERED ACCOUNTANTS

3RD FLOOR, FLAT NO 14,
AL-KARIM MANZIL,
15, PALTON ROAD,
MUMBAI 400 001
TEL. : 2261 5581
2262 0183
e mail: info@jkshah.co.in

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors referred to in paragraph 3 above, the Statement:

- i. Include the year to date financial results of the following entities:

List of Subsidiaries:

OOO Unique Pharmaceutical Laboratories, J. B. Healthcare Pvt. Ltd. LLC Unique Pharmaceutical Laboratories, Unique Pharmaceutical Laboratories FZE and Biotech Laboratories (Pty.) Ltd (w.e.f 18th December, 2015).


List of Joint Venture:

Biotech Laboratories (Pty.) Ltd (Upto 17th December, 2015)

- ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
- iii. give a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and other financial information of the Group for the year ended 31st March, 2016

For J K Shah & Co
Chartered Accountants
Firm's Registration No. : 109606W

J. K. Shah
Partner
Membership No. 3662
Place: Mumbai
Date: 20th May, 2016





J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com


CIN : L24390MH1976PLC019380

May 20, 2016

FORM - A

1	Name of the company	J.B. Chemicals & Pharmaceuticals Limited
2	Annual Financial Statements for the year ended	31st March, 2016 - Consolidated
3	Type of Audit Observation	Un modified
4	Frequency of observation	Not Applicable

For J.B. Chemicals & Pharmaceuticals Ltd.



J.B. Mody

Chairman & Managing Director



Vijay D. Bhatt

Chief Financial Officer



J. K. Shah & Co.

Auditor of the company



Durga Dass Chopra

Audit Committee Chairman

